div class=trans-pagebuttonPage 1button div class=trans-image amp-img class=trans-thumb alt=Page 1: bron: NHG standaard Cardiovasculair risicomanagement · 2019 6 10 · bron: NHG standaard Cardiovasculair risicomanagement Tabel 4 Voorkeursgeneesmiddelen in specifieke situaties src=https:reader033fdocumentsnlreader033viewer2022053118609d72f6710fd9399373a633html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divpbron: NHG standaard Cardiovasculair risicomanagementpdivdiv class=trans-pagebuttonPage 2button div class=trans-image amp-img class=trans-thumb alt=Page 2: bron: NHG standaard Cardiovasculair risicomanagement · 2019 6 10 · bron: NHG standaard Cardiovasculair risicomanagement Tabel 4 Voorkeursgeneesmiddelen in specifieke situaties src=https:reader033fdocumentsnlreader033viewer2022053118609d72f6710fd9399373a633html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divpbron: NHG standaard Cardiovasculair risicomanagementpdivdiv class=trans-pagebuttonPage 3button div class=trans-image amp-img class=trans-thumb alt=Page 3: bron: NHG standaard Cardiovasculair risicomanagement · 2019 6 10 · bron: NHG standaard Cardiovasculair risicomanagement Tabel 4 Voorkeursgeneesmiddelen in specifieke situaties src=https:reader033fdocumentsnlreader033viewer2022053118609d72f6710fd9399373a633html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divpbron: NHG standaard Cardiovasculair risicomanagementpdivdiv class=trans-pagebuttonPage 4button div class=trans-image amp-img class=trans-thumb alt=Page 4: bron: NHG standaard Cardiovasculair risicomanagement · 2019 6 10 · bron: NHG standaard Cardiovasculair risicomanagement Tabel 4 Voorkeursgeneesmiddelen in specifieke situaties src=https:reader033fdocumentsnlreader033viewer2022053118609d72f6710fd9399373a633html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divpbron: NHG standaard Cardiovasculair risicomanagementpdiv